Literature DB >> 2952767

Pathophysiological considerations in left ventricular hypertrophy.

E D Frohlich.   

Abstract

Considerable evidence is available to relate development of left ventricular hypertrophy to the maintenance and progression of hypertensive vascular disease and its associated hemodynamic changes that induce an increased left ventricular afterload. However, when critical investigators question in depth the variety of other nonhemodynamic factors that may also be associated with the development (or regression) of left ventricular hypertrophy, they are faced with three disquieting conclusions. First, knowledge of those mechanisms that account for the development and maintenance (or, for that matter, even regression) of left ventricular hypertrophy in hypertension is incomplete. Second, little is known as to how the physical hemodynamic and mechanical factors associated with the pathogenesis of hypertension are translated into the biochemical events associated with the development of cardiac muscle hypertrophy. Finally, to understand these important factors more clearly, the investigator (clinical or experimental) must design studies more precisely to control for the additional complicating, nonhemodynamic factors.

Entities:  

Mesh:

Year:  1987        PMID: 2952767

Source DB:  PubMed          Journal:  J Clin Hypertens        ISSN: 0748-450X            Impact factor:   3.738


  2 in total

1.  Prognostic implications of stress Tc-99m tetrofosmin myocardial perfusion imaging in patients with left ventricular hypertrophy.

Authors:  Abdou Elhendy; Arend F L Schinkel; Ron T van Domburg; Jeroen J Bax; Harm H H Feringa; Peter G Noordzij; Olaf Schouten; Don Poldermans
Journal:  J Nucl Cardiol       Date:  2007-07       Impact factor: 5.952

2.  Comparative effects of fosinopril and nifedipine on regression of left ventricular hypertrophy in hypertensive patients: a double-blind study.

Authors:  H G Kirpizidis; G S Papazachariou
Journal:  Cardiovasc Drugs Ther       Date:  1995-02       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.